Growth HormoneRecoveryAnti-aging

CJC-1295 / DAC

Long-Acting GHRH Analog

Typical Dose

1–2 mg / week

Route

Injectable

Variants

10mg

Overview

What is CJC-1295 / DAC?

CJC-1295 with Drug Affinity Complex (DAC) is a long-acting GHRH analog that binds to serum albumin, extending its half-life to ~8 days and producing a steady GH bleed.

Mechanism of Action

Stimulates pituitary GHRH receptors causing sustained pulsatile GH release and elevated IGF-1, supporting recovery, body composition and sleep architecture.

Key Benefits

Sustained GH and IGF-1 elevation
Improved sleep depth and recovery
Lean mass support
Convenient weekly dosing

Research Indications

Body recompositionEffective

Sleep qualityEffective

Anti-aging / skinModerate

Research Protocols

Disclaimer

These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.

Goal	Dose	Frequency	Route
Conservative	1 mg	1x weekly	Subcutaneous
Standard starting dose	1.5 mg	1x weekly	Subcutaneous
Typical maintenance	2 mg	1x weekly	Subcutaneous
Maximum	2 mg	2x weekly (split)	Subcutaneous

Peptide Interactions

Ipamorelin

Synergistic

GHRP-6

Synergistic

Insulin

Monitor

Side Effects & Safety

Common Side Effects

Water retention
Mild numbness in hands
Flushing post-injection

Safety Guidelines

For laboratory research use only — not for human consumption
Store reconstituted vials at 2–8°C, use within 30 days
Rotate injection sites to avoid local irritation
Discontinue and consult a clinician if adverse reactions occur

Quality Indicators

≥95% purity verified by HPLC
Third-party tested for sterility
Lyophilized in sealed multi-dose vial
Bacteriostatic water reconstitution
Refrigerated cold-chain shipping

What to Expect

1
Week 1–2
Improved deep sleep
2
Week 3–4
Recovery and skin quality improvements
3
Week 5–8
Body composition shifts
4
Week 9–12
Steady IGF-1 elevation

Need a different compound?

Browse all peptides